Dyslipidemia
Dyslipidemia: High blood cholesterol levels.
Lipid disorders; Hyperlipoproteinemia; Hyperlipidemia; Dyslipidemia; Hypercholesterolemia
Dyslipidemia
Dyslipidemia .ppt
Diabetes Is a CHD Risk Equivalent
Diabetes Is a CHD Risk Equivalent.ppt
New Concepts in the Evaluation and Treatment of Dyslipidemia
Nathan D. Wong, PhD, FACC
New Concepts in the Evaluation and Treatment of Dyslipidemia.
Epidemiology Clinical Trials Mgm.ppt
Approaches To Dyslipidemia Treatment in Children and Adolescents
Lorenzo Iughetti; Barbara Predieri; Patrizia Bruzzi; Fiorella Balli
Dyslipidemia_
Hypertriglyceridemia
Jenny Gordon
Tryglycerides.ppt
Diabetes Mellitus and Hypertension: Diagnosis and Management
T. Villela, M.D.
Diabetes.ppt
Awareness, Treatment and Control of Hypertension among Filipino Americans
Mariano Rey, M.D.
Treatment of Dyslipidemia
Treatment of Dyslipidemia.ppt
Lipid droplet proteins in the control of cellular lipid metabolism
Perry Bickel
Lipid droplet proteins in the control of cellular lipid metabolism.ppt
Interactive Case Presentation
Doug Kutz MD
Interactive Case Presentation.ppt
Hypertension: New Trials – Best Treatments
Karen Moncher, MD
Hypertension: New Trials – Best Treatments.
CHD is the single largest killer
CHD is the single largest killer.
Hyperlipidemia
Hyperlipidemia.ppt
Linked Metabolic Abnormalities
http://www.pitt.edu/~super4/
Cardiometabolic Syndrome
Nabil Sulaiman
http://www.pitt.edu/~super4/
http://www.pitt.edu/~super7/
Atherosclerotic Vascular Disease Risk Factors, Screening to Prevent
David R. Rudy, M.D., M.P.H.
Atherosclerotic Vascular Disease Risk Factors, Screening to Prevent.ppt
Diabetes Guidelines and Treatment
Diabetes Guidelines and Treatment.ppt
Primary Biliary Cirrhosis (PBC)
Thomas W. Faust, M.D., M.B.E.
Primary Biliary Cirrhosis.ppt
Diabetes: Guideline-Based Management
Eric L. Johnson, M.D.
DiabetesGuidelinemanagement5-
Dyslipidemia
Stanford Massie M.D.
Hyperlipidemia.
The Relationship of Weight and Obstructive Sleep Apnea
Mia Zaharna, MD, MPH
The Relationship of Weight and Obstructive Sleep Apnea.ppt
536 free full text articles
- Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats.
- Anthropometric indices associated with dyslipidemia in obese children and adolescents: a retrospective study in isfahan.
- Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
- A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia.
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.
- Response: Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005 (Diabetes Metab J 2012;36:43-55).
- Letter: Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005 (Diabetes Metab J 2012;36:43-55).
- American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis.
- Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.
- American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis: executive summary.
- The evaluation of chinese therapeutic food for the treatment of moderate dyslipidemia.
- LIPITENSION: Interplay between dyslipidemia and hypertension.
- Therapeutic Potential of Moringa oleifera Leaves in Chronic Hyperglycemia and Dyslipidemia: A Review.
- Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005.
- Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts.
- Adherence by primary care physicians to guidelines for the clinical management of dyslipidemia.
- Prevalence of dyslipidemia among Iranian patients with idiopathic tinnitus.
- Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome).
- Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis.
- Management of dyslipidemia in HIV-infected patients.
- Liver Glucokinase(A456V) Induces Potent Hypoglycemia without Dyslipidemia through a Paradoxical Induction of the Catalytic Subunit of Glucose-6-Phosphatase.
- Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
- Chronic kidney disease, dyslipidemia, and atherosclerosis.
- Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.
- [Cochleovestibular dysfunction in patients with diabetes mellitus, hypertension and dyslipidemia].
- Management of type IIb dyslipidemia.
- Dyslipidemia and eye diseases in the adult Chinese population: the Beijing eye study.
- Prevalence of dyslipidemia in patients receiving health checkups: a hospital-based study.
- Effectiveness of Motivational Interviewing in improving lipid level in patients with dyslipidemia assisted by general practitioners: Dislip-EM study protocol.
- Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
- Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China.
- Maternal manganese restriction increases susceptibility to high-fat diet-induced dyslipidemia and altered adipose function in WNIN male rat offspring.
- Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age.
- Dyslipidemia and the risk of incident hypertension in a population of community-dwelling Brazilian elderly: the Bambuà Cohort Study of Aging.
- Deficient of a clock gene, brain and muscle Arnt-like protein-1 (BMAL1), induces dyslipidemia and ectopic fat formation.
- First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study.
- Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.
- Nodular glomerulosclerosis in a non-diabetic hypertensive smoker with dyslipidemia.
- Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria.
- Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease.
- Prevalence of dyslipidemia in individuals physically active during childhood, adolescence and adult age.
- Association between job stress and newly detected combined dyslipidemia among Chinese workers: findings from the SHISO study.
- Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.
- Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management.
- [Dyslipidemia].
- [Dementia and dyslipidemia].
- Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach.
- Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.
- Dyslipidemia in dialysis patients.
- Dyslipidemia as a contributory factor in etiopathogenesis of diabetic neuropathy.
- Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat diet rats.
- [Correlation study on different dyslipidemia classification and glucose metabolism in patients with hyperlipidemia].
- Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
- Malignancy-associated dyslipidemia.
- HIV and HAART-Associated Dyslipidemia.
- Dyslipidemia associated with chronic kidney disease.
- Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer.
- A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis.
- Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.
- Abnormal high-density lipoproteins in overweight adolescents with atherogenic dyslipidemia.
- Dyslipidemia as a long-term marker for survival in pulmonary embolism.
- Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
- Dyslipidemia, low left ventricular ejection fraction and high wall motion score index are predictors of progressive left ventricular dilatation after acute myocardial infarction.
- Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
- Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.
- Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
- Prevalence and associated factors of dyslipidemia in the adult Chinese population.
- Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women.
- Results of a randomized,open-label,clinical trial investigating the effects of supplementation with Heracleumpersicum extract as an adjunctive therapy for dyslipidemia.
- Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
- [Interventions for life style related disease in the elderly: dyslipidemia].
- Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study.
- An essential role for diet in exercise-mediated protection against dyslipidemia, inflammation and atherosclerosis in ApoE⁻/⁻ mice.
- Dyslipidemia in HIV-infected individuals.
- Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study.
- [High frequency of dyslipidemia and impaired fasting glycemia in a high altitude Peruvian population].
- Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes.
- Dyslipidemia and lipid management in HIV-infected patients.
- Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity.
- The correlation between thyrotropin and dyslipidemia in a population-based study.
- Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.
- Modification of fatty acids composition in erythrocytes lipids in arterial hypertension associated with dyslipidemia.
- Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
- Impact of Pharmacy-led Dyslipidemia Interventions on Medication Safety and Therapeutic Failure in Patients.
- Study of impaired glucose tolerance, dyslipidemia, metabolic syndrome, and cardiovascular risk in a south Indian population.
- Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
- Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
- Combining genome-wide data from humans and animal models of dyslipidemia and atherosclerosis.
- Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia.
- Treatment of dyslipidemia in patients with type 2 diabetes.
- [Usability of the laboratory report and knowledge of lipid-lowering in out-patients from dyslipidemia-related departments].
- Effects of genetic variants on lipid parameters and dyslipidemia in a Chinese population.
- Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study.
- Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
- Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
- Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
- Computerized history-taking as a tool to manage dyslipidemia.
- Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).
- β-Cell adaptation/dysfunction in an animal model of dyslipidemia and insulin resistance induced by the chronic administration of a sucrose-rich diet.
- Clinical evaluation of Dyslipidemia among type II diabetic patients at Public hospital Penang, Malaysia.
- Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia.
- Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
- Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
- The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies.
- [Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia].
- Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.
- The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
- The characteristics of dyslipidemia patients with different durations in Beijing: a cross-sectional study.
- Dyslipidemia and its Treatment in HIV Infection.
- Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring.
- Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?
- Carotid ultrasound, coronary calcium, and dyslipidemia patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort.
- Effects of supervised aerobic exercise training on serum adiponectin and parameters of lipid and glucose metabolism in subjects with moderate dyslipidemia.
- Dyslipidemia in children with chronic kidney disease.
- Decreasing prevalence of the full metabolic syndrome but a persistently high prevalence of dyslipidemia among adult Arabs.
- Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.
- Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia.
- Using apolipoprotein B to manage dyslipidemia.
- [Dyslipidemia and cardiovascular risk in the adult population of Castile-Leon (Spain)].
- Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux.
- Use of statins for dyslipidemia in the pediatric population.
- Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes.
- The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
- Dyslipidemia and cardiovascular disease: a series of epidemiologic studies in Japanese populations.
- Dose-response relationship between physical activity and dyslipidemia in youth.
- Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.
- Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.
- Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.
- The contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients.
- Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.
- The correlation between dyslipidemia and coronary artery disease based on angiographic findings in an Iranian population.
- Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.
- Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia.
- Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.
- Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population.
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
- Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia.
- Treating dyslipidemia: re-evaluating the data using evidence-based medicine.
- The patient-centered medical home approach to improve dyslipidemia outcomes.
- Managing your dyslipidemia with TLC: therapeutic lifestyle changes.
- Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management.
- Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
- Caloric sweetener consumption and dyslipidemia among US adults.
- Managing mixed dyslipidemia in special populations.
- Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
- A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
- Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.
- Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.
- Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.
- A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study.
- Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
- [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
- Northern light: a commentary on the 2009 Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in adults.
- [Distribution and prevalence of dyslipidemia in Tunisia: results of the Tunisian National Nutrition Survey].
- The prevalence of hypertension, obesity and dyslipidemia in individuals of over 30 years of age belonging to minorities from the pasture area of Xinjiang.
- Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
- Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients.
- A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.
- Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis.
- Dyslipidemia in newly diagnosed diabetes mellitus: the Jakarta primary non-communicable disease risk factors surveillance 2006.
- Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
- Diminished diet-induced hyperglycemia and dyslipidemia and enhanced expression of PPARalpha and FGF21 in mice with hepatic ablation of brain-derived neurotropic factor.
- Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.
- The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia.
- Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
- Acrolein consumption induces systemic dyslipidemia and lipoprotein modification.
- Knowledge of heart disease risk among SHIELD respondents with dyslipidemia.
- Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
- Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
- Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
- Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial.
- Management of dyslipidemia in children.
- Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.
- Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.
- Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.
- Managing diabetic dyslipidemia: aggressive approach.
- Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
- Body mass index as a marker of dyslipidemia in children.
- High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses.
- Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.
- Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia.
- Molecular bases of copper and iron deficiency-associated dyslipidemia: a microarray analysis of the rat intestinal transcriptome.
- Dyslipidemia in Iranian overweight and obese children.
- 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.
- Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia.
- Dyslipidemia in chronic kidney disease: pathogenesis and intervention.
- [Dietary intake and dyslipidemia arising from combination antiretroviral therapy for HIV infection: a systematic review].
- The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
- The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.
- Mechanisms of dyslipidemia in chronic kidney disease.
- Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
- Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis.
- Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy.
- Prenatal exposure to cigarette smoke induces diet- and sex-dependent dyslipidemia and weight gain in adult murine offspring.
- Dyslipidemia in schoolchildren from private schools in Belém.
- The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.
- Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.
- Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.
- Kidney function and estimated vascular risk in patients with primary dyslipidemia.
- Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice.
- Dyslipidemia and cardiovascular risk: the importance of early prevention.
- Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia.
- Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
- Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.
- [Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].
- Nonobese, exercising children diagnosed with dyslipidemia have normal C-reactive protein.
- Efficacy and safety of rosuvastatin in the management of dyslipidemia.
- Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
- Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes.
- Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs.
- Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis.
- Influence of dyslipidemia and smoking on redox markers in humans--a critical study.
- Recommendations for management of dyslipidemia in high cardiovascular risk patients.
- Is dyslipidemia sustained during remission of nephrotic syndrome genetically determined? Evaluation of genetic polymorphisms of proteins involved in lipoprotein metabolism in children and adolescents with nephrotic syndrome.
- Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.
- The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study.
- Apolipoprotein CIII links dyslipidemia with atherosclerosis.
- Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients.
- [Factors associated with women's dyslipidemia in the post-menopause].
- [Risk factors and assistance to dyslipidemia in climacteric women].
- Contemporary trends in dyslipidemia in the Framingham Heart Study.
- Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia.
- Frequency of secondary dyslipidemia in obese children.
- Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older.
- Thyroid diseases, dyslipidemia and cardiovascular pathology.
- The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
- Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.
- Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
- A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
- [Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet].
- Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
- Therapy and clinical trials: management of diabetic dyslipidemia.
- Effects of a ferment soy product on the adipocyte area reduction and dyslipidemia control in hypercholesterolemic adult male rats.
- Common variants at 30 loci contribute to polygenic dyslipidemia.
- Pueraria mirifica phytoestrogens improve dyslipidemia in postmenopausal women probably by activating estrogen receptor subtypes.
- Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes.
- Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
- Cystic fibrosis-related dyslipidemia.
- Study of the intima-media thickening in carotid arteries of healthy elderly with high blood pressure and elderly with high blood pressure and dyslipidemia.
- Lipid profiles and prevalence of dyslipidemia in schoolchildren in south Khorasan Province, eastern Iran.
- Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia(s) in hemodialysis patients.
- Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes.
- Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
- Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
- Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).
- [Dyslipidemia prevalence and its relationship with insulin resistance in a population of apparently healthy subjects].
- CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome.
- Dyslipidemia in youth with diabetes: to treat or not to treat?
- Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance.
- Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase.
- Loss of small heterodimer partner expression in the liver protects against dyslipidemia.
- Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia.
- Oxysterol as a marker of atherogenic dyslipidemia in adolescence.
- Recognition and management of dyslipidemia in children and adolescents.
- General practitioners' adherence with clinical reminders for secondary prevention of dyslipidemia.
- The 2006 Canadian dyslipidemia guidelines will prevent more deaths while treating fewer people--but should they be further modified?
- Cardiovascular prevention (VI). Use of drugs in the primary prevention of arterial hypertension and dyslipidemia.
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.
- Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
- Effect of short-term lycopene supplementation and postprandial dyslipidemia on plasma antioxidants and biomarkers of endothelial health in young, healthy individuals.
- A novel approach using an electronic medical record to identify children and adolescents at risk for dyslipidemia: a study from the Primary Care Education and Research Learning (PEARL) network.
- Amlamax in the management of dyslipidemia in humans.
- Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
- Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
- Managing dyslipidemia in chronic kidney disease.
- The cumulative effect of core lifestyle behaviours on the prevalence of hypertension and dyslipidemia.
- [A new approach to the treatment of dyslipidemia].
- Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.
- Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
- How to improve patient compliance in dyslipidemia diagnosis and treatment.
- Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice.
- The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population.
- LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
- Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes.
- Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
- What is the relationship between white coat hypertension and dyslipidemia?
- Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.
- AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects.
- Controversial role of omega-3 fatty acids in dyslipidemia.
- Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
- Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.
- Challenges of existing pediatric dyslipidemia guidelines: call for reappraisal.
- Electronic alerts versus on-demand decision support to improve dyslipidemia treatment: a cluster randomized controlled trial.
- Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study.
- Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.
- Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status.
- [Screening for dyslipidemia based on family history combined with obesity in children].
- [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
- Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study.
- Dyslipidemia in school-children.
- Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia.
- [Antiplatelet effects of micronized fenofibrate in subjects with dyslipidemia].
- Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
- Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
- Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations.
- Goals of dyslipidemia management.
- Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
- Inflammation and dyslipidemia related to risk of spontaneous preterm birth.
- Effect of serum gamma-glutamyltransferase and obesity on the risk of dyslipidemia and poor glycemic control in type 2 diabetic patients: cross-sectional findings from the Verona Diabetes Study.
- Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.
- Dyslipidemia and H pylori in gastric xanthomatosis.
- Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity.
- Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
- Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
- [Waist circumference, dyslipidemia and hypertension in prepubertal children].
- Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein.
- Components of metabolic syndrome predicting diabetes: no role of inflammation or dyslipidemia.
- Epidemiology of dyslipidemia and economic burden on the healthcare system.
- Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
- Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients.
- Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
- [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].
- Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study.
- Integrated control of hypertension, dyslipidemia and carotid atherosclerosis in the reduction of cardiovascular risk.
- Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
- Update on dyslipidemia.
- Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans.
- Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia.
- Hepatic steatosis and plasma dyslipidemia induced by a high-sucrose diet are corrected by an acute leptin infusion.
- Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
- Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study.
- Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia.
- Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans.
- Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity.
- High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia.
- Dyslipidemia among adolescents and children from Pernambuco.
- Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics.
- Adherence to dyslipidemia treatment guidelines in diabetic patients.
- Retrospective review of the medical records of cardiology hospital outpatient clinics with the aim of determining the therapeutic approach to patients suffering from high blood pressure and/or dyslipidemia.
- The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia.
- Carbohydrate restriction is effective in improving atherogenic dyslipidemia even in the absence of weight loss.
- Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension.
- Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
- Ethnic, gender, and age-related differences in the treatment of dyslipidemia.
- Metabolic syndrome in dyslipidemia consultations.
- Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome.
- Dyslipidemia in patients with thyroid disorders.
- The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
- Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
- Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction.
- Statins for treatment of dyslipidemia in chronic kidney disease.
- Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
- Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.
- Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
- Treatment of dyslipidemia: we don't know all we think we know.
- Management of dyslipidemia in renal disease and transplantation.
- Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation.
- Surveillance and treatment of dyslipidemia in the post-infarct patient: can a nurse-led management approach make a difference?
- Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study.
- Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
- Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss.
- Intervention to improve dyslipidemia screening in hospitalized diabetics.
- [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
- The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
- The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
- Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia.
- Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction.
- Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
- Metabolic syndrome: focus on dyslipidemia.
- Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia.
- [Survey of plasma lipid value in children in Beijing area and the changes of gaseous molecule-hydrogen sulfide in the ones with dyslipidemia].
- Management strategies of dyslipidemia in the elderly: 2005.
- Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
- Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus.
- Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease.
- Linkage analysis of quantitative traits for obesity, diabetes, hypertension, and dyslipidemia on the island of Kosrae, Federated States of Micronesia.
- [Accuracy of waist circumference and waist-to-hip ratio as predictors of dyslipidemia in a cross-sectional study among blood donors in Cuiabá, Mato Grosso State, Brazil].
- Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium.
- Management of dyslipidemia in elderly diabetic patients.
- Treatment of dyslipidemia in patients with diabetes mellitus.
- Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
- Dyslipidemia in HIV patients.
- Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis.
- Dyslipidemia and the risk of incident hypertension in men.
- Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome.
- Contribution of regulatory and structural variations in APOE to predicting dyslipidemia.
- Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
- REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
- Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.
- Dietary and genetic probes of atherogenic dyslipidemia.
- Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
- Epidemiology of dyslipidemia among schoolchildren in Sousse, Tunisia.
- The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors.
- Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.
- Atherogenic dyslipidemia and the metabolic syndrome.
- Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia.
- Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia.
- Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels?
- [Effects of Anxin Granules on blood lipid and ultrastructure of aorta in rabbits with dyslipidemia].
- Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic.
- PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
- Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia.
- Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome.
- Dietary antioxidants and fat are associated with plasma antibody titers to heat shock proteins 60, 65, and 70 in subjects with dyslipidemia.
- Management of dyslipidemia in women in the post-hormone therapy era.
- A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
- The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
- Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
- Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia.
- Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
- Future strategies in the management of dyslipidemia.
- Novel approaches to the treatment of dyslipidemia.
- Dyslipidemia and thrombosis: causal relationship or epiphenomenon of sedentary lifestyle?
- Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization.
- Fructose, insulin resistance, and metabolic dyslipidemia.
- Does waist indicate dyslipidemia better than BMI in Korean adult population?
- Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
- Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
- Growth hormone overexpression in the central nervous system results in hyperphagia-induced obesity associated with insulin resistance and dyslipidemia.
- Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population.
- Pharmacologic treatment of type 2 diabetic dyslipidemia.
- Addressing cardiovascular disease in women: focus on dyslipidemia.
- Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet.
- Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing.
- Diabetic dyslipidemia and exercise affect coronary tone and differential regulation of conduit and microvessel K+ current.
- Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.
- Managing dyslipidemia in chronic kidney disease.
- Managing diabetic dyslipidemia: testing is step one.
- Adenovirus-mediated high expression of resistin causes dyslipidemia in mice.
- The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia.
- [Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia].
- Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3).
- Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population.
- Dyslipidemia guidelines.
- Dyslipidemia guidelines.
- Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia.
- Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia.
- Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.
- Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome.
- Liver-directed gene therapy for dyslipidemia and diabetes.
- Binary classification of dyslipidemia from the waist-to-hip ratio and body mass index: a comparison of linear, logistic, and CART models.
- Dyslipidemia and insulin resistance in relation to genetic admixture among Hispanics and non-Hispanic blacks of Caribbean origin.
- Search for genetic factors predisposing to atherogenic dyslipidemia.
- Does the treatment of dyslipidemia affect the risk of depression or suicidal behaviour?
- Overview of pharmacologic therapy for the treatment of dyslipidemia.
- Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
- Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
- Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells.
- Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro.
- Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model.
- Dyslipidemia in outpatients at General Hospital in Kumasi, Ghana: cross-sectional study.
- Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
- Impact of dyslipidemia in end-stage renal disease.
- Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance.
- Summary of the role of statins in the treatment of dyslipidemia.
- A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
- Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes.
- Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
- Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia.
- Adult-onset growth hormone deficiency: Relation of postprandial dyslipidemia to premature atherosclerosis.
- Medical management of hyperlipidemia/dyslipidemia.
- Effect of microsomal triglyceride transfer protein gene polymorphism in the promoter region on dyslipidemia in type 2 diabetic subjects.
- Alterations in lipid kinetics in men with HIV-dyslipidemia.
- Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans.
- Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
- Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.
- Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis.
- Effective management of patients with dyslipidemia.
- A novel therapeutic approach to dyslipidemia.
- Combination therapy for dyslipidemia.
- Underidentification and undertreatment of dyslipidemia.
- HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
- Effect of diabetes on uremic dyslipidemia.
- [Cardiovascular prevention: recommendations for approaching the vascular risk associated with dyslipidemia].
- Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia.
- Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
- Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia.
- Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol.
- Effect of ethanolic extract of Embelia ribes on dyslipidemia in diabetic rats.
- Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study.
- Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver.
- Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
- Evaluation and management of dyslipidemia in patients with HIV infection.
- Diet and exercise habits of patients with diabetes, dyslipidemia, cardiovascular disease or hypertension.
- Niacin-based therapy for dyslipidemia: past evidence and future advances.
- Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
- Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
- Decreased plasma adiponectin concentrations in women with dyslipidemia.
- Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia.
- Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
- Dyslipidemia of insulin resistance syndrome explained; need for treatment to reduce risk emphasized.
- The role of dyslipidemia and statins in venous thromboembolism.
- Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol.
- Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity.
- Mutation of the RIIbeta subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice.
- Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance.
- Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan.
- Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?
- Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
- Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
- Clinical review 124: Diabetic dyslipidemia: causes and consequences.
- [II Brazilian consensus about dyslipidemia].
- Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later.
- Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers.
- Treatment of dyslipidemia: room for improvement?
- Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
- Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
- Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
- Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia.
- Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
- Dyslipidemia in peritoneal dialysis--relation to dialytic variables.
- G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia.
- The pattern of dyslipidemia among urban African-Americans with type 2 diabetes.
- American Diabetes Association annual meeting, 1999: dyslipidemia, endothelial dysfunction, and glycosylation.
- Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
- Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes.
- Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women.
- Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet.
- Lifestyle and the development of dyslipidemia: a 4-year follow-up study of middle-aged Japanese Male Office Workers.
- Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
- Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy.
- [Hypertension and dyslipidemia].
- Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis.
- Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?
- Diabetes and dyslipidemia. A new model for transplant coronary artery disease.
- Management of dyslipidemia in adults.
- Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic.
- Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery.
- Dyslipidemia and rheumatoid arthritis.
- Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
- Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension.
- Levels of soluble cell adhesion molecules in patients with dyslipidemia.
- Human lipoprotein lipase deficiency: does chronic dyslipidemia lead to increased oxidative stress and mitochondrial DNA damage in blood cells?
- Effects of hypertension and dyslipidemia on the decline in renal function.
- Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia.
- Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia.
- Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene.
- Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins.
- Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
- Resistance to insulin-stimulated glucose uptake and dyslipidemia in Asian Indians.
- Dyslipidemia in patients with chronic renal failure and in renal transplant patients.
- Dyslipidemia in chronic renal failure patients.
- Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
- IgA anti-lipoprotein antibodies in autoimmune dyslipidemia are restricted to IgA1 subclass.
- The insulin resistance-dyslipidemia syndrome: the most prevalent cause of coronary artery disease?
- Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia.
|
Bookmark this post:
|
|
Posts
0 comments:
Post a Comment